Roflumilast Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Roflumilast comprises 117 peer-reviewed publications across 15 journals, 19 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Alzheimer Disease, Pulmonary Disease, Chronic Obstructive, Colitis, Ulcerative, and Bronchiectasis. Most recent publication: Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)., Pediatr Dermatol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells.
    Zúñiga TM, Baker FL, Smith KA, et al. · Front Immunol · 2022
    PubMed: PMID 36189306 · NCT06643221 (Allo-X) · Leukemia
  2. Clonal Kinetics and Single-Cell Transcriptional Profiles of T Cells Mobilized to Blood by Acute Exercise.
    Zúñiga TM, Baker FL, Smith KA, et al. · Med Sci Sports Exerc · 2023
    PubMed: PMID 36719647 · NCT06643221 (Allo-X) · Leukemia
  3. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults.
    Van Duinen MA, Sambeth A, Heckman PRA, et al. · Neuropharmacology · 2018
    PubMed: PMID 29241652 · NCT01433666 (EEGrofl) · Dementia
  4. Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial.
    Heckman PRA, Van Duinen MA, Blokland A, et al. · Psychopharmacology (Berl) · 2018
    PubMed: PMID 29098341 · NCT01433666 (EEGrofl) · Dementia
  5. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
    Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. · Lancet · 2009
    PubMed: PMID 19716961 · NCT00424268 (HELIOS) · Pulmonary Disease, Chronic Obstructive
  6. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM, Rabe KF, Goehring UM, et al. · Lancet · 2009
    PubMed: PMID 19716960 · NCT00297115 · Pulmonary Disease, Chronic Obstructive
  7. Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice.
    Batatinha H, Diak DM, Niemiro GM, et al. · Front Immunol · 2023
    PubMed: PMID 37077913 · NCT06643221 (Allo-X) · Leukemia
  8. Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition.
    Baker FL, Smith KA, Mylabathula PL, et al. · Cancer Res Commun · 2024
    PubMed: PMID 38592213 · NCT06643221 (Allo-X) · Leukemia

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00297102Pulmonary Disease, Chronic ObstructiveCOPD Exacerbation Rate (Moderate or Severe)
52 weeks treatment period
Placebo1.266 exacerbations per patient per year
Roflumilast1.077 exacerbations per patient per year
NCT00297102Pulmonary Disease, Chronic ObstructivePre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Change from baseline over 52 weeks of treatment
Placebo8 mL (±8 Standard Error)
Roflumilast46 mL (±8 Standard Error)
NCT00297115Pulmonary Disease, Chronic ObstructiveCOPD Exacerbation Rate (Moderate or Severe)
52 weeks treatment period
Placebo1.485 exacerbations per patient per year
Roflumilast1.210 exacerbations per patient per year
NCT00297115Pulmonary Disease, Chronic ObstructivePre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Change from baseline over 52 weeks of treatment
Placebo-25 mL (±7 Standard Error)
Roflumilast33 mL (±7 Standard Error)
NCT00313209
EOS
Pulmonary Disease, Chronic ObstructivePre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Change from baseline over 24 weeks of treatment
Placebo-10 mL (±9 Standard Error)
Roflumilast39 mL (±9 Standard Error)
NCT00424268
HELIOS
Pulmonary Disease, Chronic ObstructivePre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Change from baseline over 24 weeks of treatment
Placebo-16 mL (±12 Standard Error)
Roflumilast65 mL (±12 Standard Error)
NCT01313494
ACROSS
Pulmonary Disease, Chronic ObstructiveChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Baseline to Week 24
Placebo-0.022 liters (±0.009 Standard Error)
Roflumilast0.049 liters (±0.009 Standard Error)
NCT01509677Pulmonary Disease, Chronic ObstructiveChange in Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue
Baseline to 16 weeks
Placebo29.4 cells/mm^2 (±298.88 Standard Deviation)
R50013.4 cells/mm^2 (±302.69 Standard Deviation)
NCT01509677Pulmonary Disease, Chronic ObstructiveNumber of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue.
16 weeks
Placebo427.1 CD8+ cells count (±261.42 Standard Deviation)
R500442.4 CD8+ cells count (±312.74 Standard Deviation)
NCT01973998Pulmonary Disease, Chronic ObstructiveTime to All-cause Mortality or Re-hospitalization During the 180 Days Post-randomization.
180 days
Placebo55 Days to event
Roflumilast54 Days to event
NCT02165826
OPTIMIZE
Pulmonary Disease, Chronic ObstructivePercentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason
Baseline to Week 12 (Main Period)
Roflumilast 250 μg OD Then 500 μg OD18.4 percentage of participants
Roflumilast 500 μg EOD Then 500 μg OD20.1 percentage of participants
Roflumilast 500 μg OD24.6 percentage of participants
NCT02340520Pulmonary Disease, Chronic ObstructiveBronchodilation
Baseline, Week 1 and 2
Theophylline and Roflumilast1.18 liters (±0.51 Standard Deviation)
Theophylline and Roflumilast2.72 liters (±0.78 Standard Deviation)
Theophylline and Roflumilast1.22 liters (±0.51 Standard Deviation)
Theophylline and Roflumilast2.90 liters (±0.82 Standard Deviation)
Theophylline and Roflumilast1.18 liters (±0.51 Standard Deviation)
Theophylline and Roflumilast2.72 liters (±0.68 Standard Deviation)
Theophylline and Roflumilast1.25 liters (±0.58 Standard Deviation)
Theophylline and Roflumilast2.79 liters (±0.71 Standard Deviation)
Theophylline and Roflumilast1.18 liters (±0.51 Standard Deviation)
Theophylline and Roflumilast2.81 liters (±0.61 Standard Deviation)
Theophylline and Roflumilast1.24 liters (±0.54 Standard Deviation)
Theophylline and Roflumilast2.80 liters (±0.65 Standard Deviation)
Theophylline and Roflumilast1.30 liters (±0.47 Standard Deviation)
Theophylline and Roflumilast2.98 liters (±0.67 Standard Deviation)
NCT04211363
DERMIS-1
—Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8
Baseline (Day 1) and Week 8
Rofumilast Cream 0.3%108 Participants
Vehicle Cream8 Participants
NCT04773587
INTEGUMENT-I
—Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4
Week 4
Roflumilast Cream 0.15%32.0 percentage of participants
Vehicle Cream15.2 percentage of participants
NCT04773600—Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4
Week 4
Roflumilast Cream 0.15%28.9 percentage of participants
Vehicle Cream12.0 percentage of participants
NCT04845620—Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4
Week 4
Roflumilast Cream 0.05%25.4 percentage of participants
Vehicle Cream10.7 percentage of participants
NCT04973228Dermatitis, SeborrheicAchievement of Success on the Investigator Global Assessment (IGA) at Week 8
Week 8
Roflumilast Foam 0.3%80 percentage of participants
Vehicle Foam58 percentage of participants
NCT05028582
ARRECTOR
—Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 8
Week 8
Roflumilast Foam 0.3%45.5 percentage of participants
Vehicle Foam20.1 percentage of participants
NCT05028582
ARRECTOR
—Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8
Week 8
Roflumilast Foam 0.3%66.4 percentage of participants
Vehicle Foam27.8 percentage of participants

Publications by year

1990–2026: 117 publications.

1990
1
1997
1
1999
1
2002
1
2003
1
2005
1
2006
1
2007
2
2008
1
2009
2
2010
5
2011
6
2012
3
2013
10
2014
7
2015
4
2016
12
2017
7
2018
5
2019
9
2020
6
2021
2
2022
6
2023
10
2024
4
2025
6
2026
3

Publications by indication

Alzheimer Disease (26)

  • The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    J Prev Alzheimers Dis · 2024 · PMID 26478889 · NCT02835716
  • Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.
    J Intern Med · 2017 · PMID 26940242 · NCT02835716
  • Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics.
    Expert Rev Neurother · 2017 · PMID 27293026 · NCT02835716
  • The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging.
    Front Aging Neurosci · 2016 · PMID 27199739 · NCT02835716
  • Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
    Neurotherapeutics · 2016 · PMID 25371167 · NCT02835716

Pulmonary Disease, Chronic Obstructive (25)

  • Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.
    Respirology · 2021 · PMID 32725799 · NCT01630200
  • Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
    Int J Chron Obstruct Pulmon Dis · 2020 · PMID 31354255 · NCT02018432
  • Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
    Lancet Respir Med · 2019 · PMID 30224319 · NCT01509677
  • Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
    Am J Respir Crit Care Med · 2019 · PMID 29763572 · NCT01443845
  • The Tendril Plot-a novel visual summary of the incidence, significance and temporal aspects of adverse events in clinical trials.
    J Am Med Inform Assoc · 2019 · PMID 29579254 · NCT01443845

Colitis, Ulcerative (16)

  • Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
    J Crohns Colitis · 2025 · PMID 30272117 · NCT05684484
  • Clinico-Epidemiological Characteristics of Patients With Inflammatory Bowel Disease in Egypt: A Nationwide Multicenter Study.
    Front Med (Lausanne) · 2022 · PMID 35514748 · NCT05684484
  • Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
    J Med Chem · 2020 · PMID 31099559 · NCT05684484
  • DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling.
    Biochem Pharmacol · 2020 · PMID 32251674 · NCT05684484
  • Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
    Br J Pharmacol · 2020 · PMID 30883697 · NCT05684484

Bronchiectasis (9)

  • Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial.
    Sarcoidosis Vasc Diffuse Lung Dis · 2022 · PMID 34744427 · NCT01830959
  • Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
    Chron Respir Dis · 2018 · PMID 27507832 · NCT03988816
  • Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.
    Eur Respir J · 2017 · PMID 26541539 · NCT03988816
  • Non-cystic fibrosis bronchiectasis.
    Am J Respir Crit Care Med · 2013 · PMID 23898922 · NCT03988816
  • Phosphodiesterase-4 inhibitor therapy for lung diseases.
    Am J Respir Crit Care Med · 2013 · PMID 23656508 · NCT03988816

Leukemia (5)

  • Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.
    Blood Adv · 2026 · PMID 41538301 · NCT06643221
  • Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition.
    Cancer Res Commun · 2024 · PMID 38592213 · NCT06643221
  • Clonal Kinetics and Single-Cell Transcriptional Profiles of T Cells Mobilized to Blood by Acute Exercise.
    Med Sci Sports Exerc · 2023 · PMID 36719647 · NCT06643221
  • Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice.
    Front Immunol · 2023 · PMID 37077913 · NCT06643221
  • Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells.
    Front Immunol · 2022 · PMID 36189306 · NCT06643221

Obesity (5)

  • Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study.
    Diabetes Metab Syndr Obes · 2022 · PMID 31213865 · NCT01862029
  • Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
    J Ovarian Res · 2016 · PMID 26032655 · NCT02187250
  • Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
    J Clin Endocrinol Metab · 2012 · PMID 22723325 · NCT01862029
  • cAMP enhances insulin secretion by an action on the ATP-sensitive K+ channel-independent pathway of glucose signaling in rat pancreatic islets.
    Diabetes · 1999 · PMID 10331404 · NCT01862029
  • Peripheral nerve surgery today: turning point or continuous development?
    J Hand Surg Br · 1990 · PMID 2230491 · NCT01862029

Publications by journal

Trial-results highlights

Clinical trials have investigated the effects of Roflumilast in patients with Chronic Obstructive Pulmonary Disease (COPD). In studies evaluating the COPD exacerbation rate (moderate or severe) over a 52-week treatment period, results varied by trial. In NCT00297102, the mean exacerbation rate was 1.266 per patient per year in the placebo arm and 1.077 per patient per year in the Roflumilast arm. Another study, NCT00297115, reported a mean exacerbation rate of 1.485 per patient per year for the placebo arm and 1.210 per patient per year for the Roflumilast arm.

Changes in pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) were also assessed. Over 52 weeks of treatment in NCT00297102, the least squares mean change from baseline in FEV1 was 8 mL for the placebo arm and 46 mL for the Roflumilast arm. In NCT00297115, over the same 52-week period, the least squares mean change from baseline in FEV1 was -25 mL for the placebo arm and 33 mL for the Roflumilast arm. Shorter-term studies over 24 weeks also measured FEV1 changes. In NCT00313209, the least squares mean change from baseline was -10 mL for placebo and 39 mL for Roflumilast. Similarly, NCT00424268 reported a least squares mean change of -16 mL for placebo and 65 mL for Roflumilast.

Further FEV1 data from NCT01313494 showed a least squares mean change from baseline to week 24 of -0.022 liters for the placebo arm and 0.049 liters for the Roflumilast arm. Additionally, NCT01509677 investigated the change in the number of CD8+ inflammatory cells in bronchial biopsy tissue from baseline to 16 weeks. The mean change was 29.4 cells/mm^2 for the placebo arm and 13.4 cells/mm^2 for the R500 (Roflumilast) arm. All values presented are sourced from primary registry reporting; individual publications should be consulted for clinical decisions.

All Roflumilast publications (117)

2026 (3 papers)

  1. Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).
    Eichenfield LF, Gonzalez ME, Boguniewicz M, et al. · Pediatr Dermatol · 2026 · Derived
    PubMed: PMID 41795905 · NCT04845620
  2. First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL.
    Duque AED, Ferrari PSSM, Ethiraj P, et al. · Cancers (Basel) · 2026 · Derived
    PubMed: PMID 39594812 · NCT03458546 · Lymphoma, B-Cell
  3. Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.
    Batatinha H, Valenzuela AM, Filioglou D, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41538301 · NCT06643221 (Allo-X) · Leukemia

2025 (6 papers)

  1. Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.
    Papp KA, Del Rosso JQ, Lebwohl MG, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 41134450 · NCT04211363 (DERMIS-1)
  2. Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
    Gooderham MJ, Alonso-Llamazares J, Bagel J, et al. · JAMA Dermatol · 2025 · Derived
    PubMed: PMID 40332898 · NCT05028582 (ARRECTOR)
  3. Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study.
    Elsharab A, Nooh MZ, Matard RS, et al. · Diabetes Metab Syndr Obes · 2025 · Derived
    PubMed: PMID 41256904 · NCT05369793 · Diabetes Mellitus, Type 2
  4. Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.
    Eichenfield LF, Serrao R, Prajapati VH, et al. · Pediatr Dermatol · 2025 · Derived
    PubMed: PMID 39980188 · NCT04845620
  5. Oral Roflumilast Suppresses Proinflammatory Cytokine Signaling and Reduces CD4+ T-Cell and Neutrophil Infiltration in Psoriasis.
    Baez E, Gyldenløve M, Ben Abdallah H, et al. · J Invest Dermatol · 2025 · Derived
    PubMed: PMID 40403838 · NCT04549870 (PSORRO) · Psoriasis
  6. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
    Trivedi PJ, Adams DH · J Crohns Colitis · 2025 · Background
    PubMed: PMID 30272117 · NCT05684484 · Colitis, Ulcerative

2024 (4 papers)

  1. Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition.
    Baker FL, Smith KA, Mylabathula PL, et al. · Cancer Res Commun · 2024 · Trial result
    PubMed: PMID 38592213 · NCT06643221 (Allo-X) · Leukemia
  2. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
    Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. · JAMA Dermatol · 2024 · Derived
    PubMed: PMID 39292443 · NCT04773600
  3. A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial.
    Possemis N, Verhey F, Prickaerts J, et al. · Trials · 2024 · Derived
    PubMed: PMID 38438923 · NCT04658654 (ROMEMA) · Cognitive Dysfunction
  4. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    Cavedo E, Lista S, Khachaturian Z, et al. · J Prev Alzheimers Dis · 2024 · Background
    PubMed: PMID 26478889 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2023 (10 papers)

  1. Clonal Kinetics and Single-Cell Transcriptional Profiles of T Cells Mobilized to Blood by Acute Exercise.
    Zúñiga TM, Baker FL, Smith KA, et al. · Med Sci Sports Exerc · 2023 · Trial result
    PubMed: PMID 36719647 · NCT06643221 (Allo-X) · Leukemia
  2. Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice.
    Batatinha H, Diak DM, Niemiro GM, et al. · Front Immunol · 2023 · Trial result
    PubMed: PMID 37077913 · NCT06643221 (Allo-X) · Leukemia
  3. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
    Zirwas MJ, Draelos ZD, DuBois J, et al. · JAMA Dermatol · 2023 · Derived
    PubMed: PMID 37133856 · NCT04091646 · Dermatitis, Seborrheic
  4. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.
    Thurston AW, Osborne DW, Snyder S, et al. · Am J Clin Dermatol · 2023 · Derived
    PubMed: PMID 36422852 · NCT04211363 (DERMIS-1)
  5. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
    Stein Gold L, Alonso-Llamazares J, Draelos ZD, et al. · Am J Clin Dermatol · 2023 · Derived
    PubMed: PMID 36370336 · NCT03638258 (ARQ-151-201)
  6. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO).
    Gyldenløve M, Meteran H, Sørensen JA, et al. · Lancet Reg Health Eur · 2023 · Derived
    PubMed: PMID 37465323 · NCT04549870 (PSORRO) · Psoriasis
  7. Roflumilast May Increase Risk of Exacerbations When Used to Treat Poorly Controlled Asthma in People with Obesity.
    Dixon AE, Que LG, Kalhan R, et al. · Ann Am Thorac Soc · 2023 · Derived
    PubMed: PMID 36170654 · NCT03532490 (TRIM) · Asthma
  8. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Dermatitis, Atopic
  9. A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.
    Pixley JN, Schaetzle T, Feldman SR, et al. · Ann Pharmacother · 2023 · Background
    PubMed: PMID 36420929 · NCT06440473
  10. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Dermatitis, Atopic

2022 (6 papers)

  1. Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells.
    Zúñiga TM, Baker FL, Smith KA, et al. · Front Immunol · 2022 · Trial result
    PubMed: PMID 36189306 · NCT06643221 (Allo-X) · Leukemia
  2. Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study.
    Muo IM, MacDonald SD, Madan R, et al. · Diabetes Metab Syndr Obes · 2022 · Derived
    PubMed: PMID 31213865 · NCT01862029 · Obesity
  3. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
    Lebwohl MG, Kircik LH, Moore AY, et al. · JAMA · 2022 · Derived
    PubMed: PMID 36125472 · NCT04211363 (DERMIS-1)
  4. Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial.
    Baughman RP, Judson MA, Culver DA, et al. · Sarcoidosis Vasc Diffuse Lung Dis · 2022 · Derived
    PubMed: PMID 34744427 · NCT01830959 (REFS) · Bronchiectasis
  5. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Dermatitis, Atopic
  6. Clinico-Epidemiological Characteristics of Patients With Inflammatory Bowel Disease in Egypt: A Nationwide Multicenter Study.
    Elbadry M, Nour MO, Hussien M, et al. · Front Med (Lausanne) · 2022 · Background
    PubMed: PMID 35514748 · NCT05684484 · Colitis, Ulcerative

2021 (2 papers)

  1. Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.
    Urban MH, Kreibich N, Gleiss A, et al. · Respirology · 2021 · Derived
    PubMed: PMID 32725799 · NCT01630200 (ELASTIC) · Pulmonary Disease, Chronic Obstructive
  2. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
    Gilleen J, Farah Y, Davison C, et al. · Psychopharmacology (Berl) · 2021 · Derived
    PubMed: PMID 30536081 · NCT02079844 · Schizophrenia

2020 (6 papers)

  1. Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
    Park TS, Kang J, Lee JS, et al. · Int J Chron Obstruct Pulmon Dis · 2020 · Derived
    PubMed: PMID 31354255 · NCT02018432 · Pulmonary Disease, Chronic Obstructive
  2. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
    Lebwohl MG, Papp KA, Stein Gold L, et al. · N Engl J Med · 2020 · Derived
    PubMed: PMID 32668113 · NCT03638258 (ARQ-151-201)
  3. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
    Zhang X, Dong G, Li H, et al. · J Med Chem · 2020 · Background
    PubMed: PMID 31099559 · NCT05684484 · Colitis, Ulcerative
  4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS, Landewé RBM, Bijlsma JWJ, et al. · Ann Rheum Dis · 2020 · Background
    PubMed: PMID 31969328 · NCT07566351 · Arthritis, Rheumatoid
  5. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling.
    Li H, Li J, Zhang X, et al. · Biochem Pharmacol · 2020 · Background
    PubMed: PMID 32251674 · NCT05684484 · Colitis, Ulcerative
  6. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
    Li H, Fan C, Feng C, et al. · Br J Pharmacol · 2020 · Background
    PubMed: PMID 30883697 · NCT05684484 · Colitis, Ulcerative

2019 (9 papers)

  1. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
    Rabe KF, Watz H, Baraldo S, et al. · Lancet Respir Med · 2019 · Derived
    PubMed: PMID 30224319 · NCT01509677 · Pulmonary Disease, Chronic Obstructive
  2. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
    Martinez FJ, Rabe KF, Calverley PMA, et al. · Am J Respir Crit Care Med · 2019 · Derived
    PubMed: PMID 29763572 · NCT01443845 · Pulmonary Disease, Chronic Obstructive
  3. The Tendril Plot-a novel visual summary of the incidence, significance and temporal aspects of adverse events in clinical trials.
    Karpefors M, Weatherall J · J Am Med Inform Assoc · 2019 · Derived
    PubMed: PMID 29579254 · NCT01443845 · Pulmonary Disease, Chronic Obstructive
  4. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
    Facius A, Marostica E, Gardiner P, et al. · Clin Pharmacokinet · 2019 · Derived
    PubMed: PMID 29797235 · NCT01329029 (REACT) · Pulmonary Disease, Chronic Obstructive
  5. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Zundler S, Becker E, Schulze LL, et al. · Gut · 2019 · Background
    PubMed: PMID 31127023 · NCT05684484 · Colitis, Ulcerative
  6. Phosphodiesterase 4 inhibitors.
    Zebda R, Paller AS · J Am Acad Dermatol · 2019 · Background
    PubMed: PMID 29248522 · NCT05684484 · Colitis, Ulcerative
  7. Targeting immune cell circuits and trafficking in inflammatory bowel disease.
    Neurath MF · Nat Immunol · 2019 · Background
    PubMed: PMID 31235952 · NCT05684484 · Colitis, Ulcerative
  8. Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury.
    Kosutova P, Mikolka P, Kolomaznik M, et al. · Physiol Res · 2019 · Background
    PubMed: PMID 30607971 · NCT05684484 · Colitis, Ulcerative
  9. Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis.
    Fujita Y, Khateb A, Li Y, et al. · Cell Rep · 2019 · Background
    PubMed: PMID 30232010 · NCT05684484 · Colitis, Ulcerative

2018 (5 papers)

  1. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults.
    Van Duinen MA, Sambeth A, Heckman PRA, et al. · Neuropharmacology · 2018 · Trial result
    PubMed: PMID 29241652 · NCT01433666 (EEGrofl) · Dementia
  2. Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial.
    Heckman PRA, Van Duinen MA, Blokland A, et al. · Psychopharmacology (Berl) · 2018 · Trial result
    PubMed: PMID 29098341 · NCT01433666 (EEGrofl) · Dementia
  3. Effect of roflumilast in patients with severe COPD and a history of hospitalisation.
    Rabe KF, Calverley PMA, Martinez FJ, et al. · Eur Respir J · 2018 · Derived
    PubMed: PMID 28679611 · NCT01329029 (REACT) · Pulmonary Disease, Chronic Obstructive
  4. Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.
    Facius A, Krause A, Claret L, et al. · J Clin Pharmacol · 2018 · Derived
    PubMed: PMID 28419462 · NCT00430729 · Pulmonary Disease, Chronic Obstructive
  5. Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
    Fjaellegaard K, Sin MD, Browatzki A, et al. · Chron Respir Dis · 2018 · Background
    PubMed: PMID 27507832 · NCT03988816 · Bronchiectasis

2017 (7 papers)

  1. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
    Martinez FJ, Rabe KF, Sethi S, et al. · Am J Respir Crit Care Med · 2017 · Derived
    PubMed: PMID 27585384 · NCT01443845 · Pulmonary Disease, Chronic Obstructive
  2. Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
    Mackay AJ, Patel ARC, Singh R, et al. · Am J Respir Crit Care Med · 2017 · Derived
    PubMed: PMID 28146642 · NCT01473758 (TREAT) · Pulmonary Disease, Chronic Obstructive
  3. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.
    Quint JK, Millett ER, Joshi M, et al. · Eur Respir J · 2017 · Background
    PubMed: PMID 26541539 · NCT03988816 · Bronchiectasis
  4. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K, Kass DA · Annu Rev Pharmacol Toxicol · 2017 · Background
    PubMed: PMID 27732797 · NCT05684484 · Colitis, Ulcerative
  5. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.
    Galluzzi S, Marizzoni M, Babiloni C, et al. · J Intern Med · 2017 · Background
    PubMed: PMID 26940242 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  6. Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics.
    Deardorff WJ, Grossberg GT · Expert Rev Neurother · 2017 · Background
    PubMed: PMID 27293026 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  7. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.
    de Souza HSP, Fiocchi C, Iliopoulos D, et al. · Nat Rev Gastroenterol Hepatol · 2017 · Background
    PubMed: PMID 28831186 · NCT05684484 · Colitis, Ulcerative

2016 (12 papers)

  1. A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
    Wells JM, Jackson PL, Viera L, et al. · Am J Respir Crit Care Med · 2016 · Derived
    PubMed: PMID 26151090 · NCT01572948 · Pulmonary Disease, Chronic Obstructive
  2. Roflumilast for asthma: Efficacy findings in placebo-controlled studies.
    Meltzer EO, Chervinsky P, Busse W, et al. · Pulm Pharmacol Ther · 2016 · Derived
    PubMed: PMID 26498386 · NCT00073177 · Asthma
  3. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
    Jensterle M, Salamun V, Kocjan T, et al. · J Ovarian Res · 2016 · Derived
    PubMed: PMID 26032655 · NCT02187250 · Obesity
  4. Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies.
    Chervinsky P, Meltzer EO, Busse W, et al. · Pulm Pharmacol Ther · 2016 · Derived
    PubMed: PMID 26612545 · NCT00073177 · Asthma
  5. Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.
    Bateman ED, Bousquet J, Aubier M, et al. · Pulm Pharmacol Ther · 2016 · Derived
    PubMed: PMID 26456372 · NCT00163475 · Asthma
  6. Roflumilast for asthma: Efficacy findings in mechanism of action studies.
    Bardin P, Kanniess F, Gauvreau G, et al. · Pulm Pharmacol Ther · 2016 · Derived
    PubMed: PMID 26296794 · NCT01365533
  7. The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging.
    Zhou Y, Tan C, Wen D, et al. · Front Aging Neurosci · 2016 · Background
    PubMed: PMID 27199739 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  8. The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases.
    Raker VK, Becker C, Steinbrink K, et al. · Front Immunol · 2016 · Background
    PubMed: PMID 27065076 · NCT05684484 · Colitis, Ulcerative
  9. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Dermatitis, Atopic
  10. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
    Gurney ME, D'Amato EC, Burgin AB, et al. · Neurotherapeutics · 2016 · Background
    PubMed: PMID 25371167 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  11. A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.
    Green RC, Christensen KD, Cupples LA, et al. · Alzheimers Dement · 2016 · Background
    PubMed: PMID 25499536 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  12. Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial.
    Christensen KD, Roberts JS, Whitehouse PJ, et al. · Ann Intern Med · 2016 · Background
    PubMed: PMID 26810768 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2015 (4 papers)

  1. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ, Calverley PM, Goehring UM, et al. · Lancet · 2015 · Derived
    PubMed: PMID 25684586 · NCT01329029 (REACT) · Pulmonary Disease, Chronic Obstructive
  2. Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals.
    Xekardaki A, Rodriguez C, Montandon ML, et al. · Radiology · 2015 · Background
    PubMed: PMID 25291458 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  3. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
    Heckman PR, Wouters C, Prickaerts J, et al. · Curr Pharm Des · 2015 · Background
    PubMed: PMID 25159073 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  4. Ulcerative colitis: epidemiology, diagnosis, and management.
    Feuerstein JD, Cheifetz AS · Mayo Clin Proc · 2015 · Background
    PubMed: PMID 25199861 · NCT05684484 · Colitis, Ulcerative

2014 (7 papers)

  1. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
    Zheng J, Yang J, Zhou X, et al. · Chest · 2014 · Derived
    PubMed: PMID 24135893 · NCT01313494 (ACROSS) · Pulmonary Disease, Chronic Obstructive
  2. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
    Hanania NA, Calverley PM, Dransfield MT, et al. · Respir Med · 2014 · Derived
    PubMed: PMID 24120253 · NCT00297102 · Pulmonary Disease, Chronic Obstructive
  3. Early indications of future cognitive decline: stable versus declining controls.
    Rizk-Jackson A, Insel P, Petersen R, et al. · PLoS One · 2014 · Background
    PubMed: PMID 24040166 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  4. Preventing cognitive decline in preclinical Alzheimer's disease.
    Riedel WJ · Curr Opin Pharmacol · 2014 · Background
    PubMed: PMID 24565007 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  5. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease.
    Peters KR, Lynn Beattie B, Feldman HH, et al. · Prog Neurobiol · 2014 · Background
    PubMed: PMID 23348495 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  6. Ushering in the study and treatment of preclinical Alzheimer disease.
    Langbaum JB, Fleisher AS, Chen K, et al. · Nat Rev Neurol · 2014 · Background
    PubMed: PMID 23752908 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  7. Emerging therapeutics for Alzheimer's disease.
    Chiang K, Koo EH · Annu Rev Pharmacol Toxicol · 2014 · Background
    PubMed: PMID 24392696 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2013 (10 papers)

  1. Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
    Wedzicha JA, Rabe KF, Martinez FJ, et al. · Chest · 2013 · Derived
    PubMed: PMID 23117188 · NCT00297102 · Pulmonary Disease, Chronic Obstructive
  2. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline.
    Vom Berg J, Prokop S, Miller KR, et al. · Nat Med · 2013 · Background
    PubMed: PMID 23178247 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  3. Cutaneous manifestations of gastrointestinal disease: part II.
    Thrash B, Patel M, Shah KR, et al. · J Am Acad Dermatol · 2013 · Background
    PubMed: PMID 23317981 · NCT05684484 · Colitis, Ulcerative
  4. Non-cystic fibrosis bronchiectasis.
    McShane PJ, Naureckas ET, Tino G, et al. · Am J Respir Crit Care Med · 2013 · Background
    PubMed: PMID 23898922 · NCT03988816 · Bronchiectasis
  5. Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals.
    Lazarczyk MJ, Hof PR, Bouras C, et al. · BMC Med · 2013 · Background
    PubMed: PMID 23098093 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  6. Neuroinflammatory cytokine signaling and Alzheimer's disease.
    Griffin WS · N Engl J Med · 2013 · Background
    PubMed: PMID 23425171 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  7. Phosphodiesterases as therapeutic targets for Alzheimer's disease.
    García-Osta A, Cuadrado-Tejedor M, García-Barroso C, et al. · ACS Chem Neurosci · 2013 · Background
    PubMed: PMID 23173065 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  8. The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review.
    Caltagirone C, Ferrannini L, Marchionni N, et al. · Aging Clin Exp Res · 2013 · Background
    PubMed: PMID 22961121 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  9. Phosphodiesterase-4 inhibitor therapy for lung diseases.
    Beghè B, Rabe KF, Fabbri LM, et al. · Am J Respir Crit Care Med · 2013 · Background
    PubMed: PMID 23656508 · NCT03988816 · Bronchiectasis
  10. Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study.
    Bangen KJ, Restom K, Liu TT, et al. · J Alzheimers Dis · 2013 · Background
    PubMed: PMID 22531427 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2012 (3 papers)

  1. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.
    Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, et al. · Respir Res · 2012 · Derived
    PubMed: PMID 22029856 · NCT01365533
  2. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
    Calverley PM, Martinez FJ, Fabbri LM, et al. · Int J Chron Obstruct Pulmon Dis · 2012 · Derived
    PubMed: PMID 22791991 · NCT01329029 (REACT) · Pulmonary Disease, Chronic Obstructive
  3. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
    Wouters EF, Bredenbröker D, Teichmann P, et al. · J Clin Endocrinol Metab · 2012 · Background
    PubMed: PMID 22723325 · NCT01862029 · Obesity

2011 (6 papers)

  1. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI, Calverley PM, Goehring UM, et al. · Respir Res · 2011 · Derived
    PubMed: PMID 21272339 · NCT00076089 · Pulmonary Disease, Chronic Obstructive
  2. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
    de Mey C, Nassr N, Lahu G, et al. · BMC Clin Pharmacol · 2011 · Derived
    PubMed: PMID 21631929 · NCT00940329
  3. Prediction of cognitive decline in healthy older adults using fMRI.
    Woodard JL, Seidenberg M, Nielson KA, et al. · J Alzheimers Dis · 2011 · Background
    PubMed: PMID 20634590 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  4. The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD.
    Sava F, Laviolette L, Bernard S, et al. · BMC Pulm Med · 2011 · Background
    PubMed: PMID 21054892 · NCT01701934 (RAMBO) · Pulmonary Disease, Chronic Obstructive
  5. Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data.
    Haller S, Nguyen D, Rodriguez C, et al. · J Alzheimers Dis · 2011 · Background
    PubMed: PMID 20847435 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  6. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease.
    Chincarini A, Bosco P, Calvini P, et al. · Neuroimage · 2011 · Background
    PubMed: PMID 21718788 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2010 (5 papers)

  1. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
    Cazzola M, Picciolo S, Matera MG, et al. · Expert Opin Pharmacother · 2010 · Derived
    PubMed: PMID 20102307 · NCT00424268 (HELIOS) · Pulmonary Disease, Chronic Obstructive
  2. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.
    Vernarelli JA, Roberts JS, Hiraki S, et al. · Am J Clin Nutr · 2010 · Background
    PubMed: PMID 20219963 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  3. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner.
    Sousa LP, Lopes F, Silva DM, et al. · J Leukoc Biol · 2010 · Background
    PubMed: PMID 20103769 · NCT04090294 · Bronchiectasis
  4. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.
    Li NC, Lee A, Whitmer RA, et al. · BMJ · 2010 · Background
    PubMed: PMID 20068258 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  5. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study.
    Lam KB, Jordan RE, Jiang CQ, et al. · Eur Respir J · 2010 · Background
    PubMed: PMID 19574332 · NCT01701934 (RAMBO) · Pulmonary Disease, Chronic Obstructive

2009 (2 papers)

  1. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
    Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. · Lancet · 2009 · Trial result
    PubMed: PMID 19716961 · NCT00424268 (HELIOS) · Pulmonary Disease, Chronic Obstructive
  2. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM, Rabe KF, Goehring UM, et al. · Lancet · 2009 · Trial result
    PubMed: PMID 19716960 · NCT00297115 · Pulmonary Disease, Chronic Obstructive

2008 (1 paper)

  1. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
    Chao S, Roberts JS, Marteau TM, et al. · Alzheimer Dis Assoc Disord · 2008 · Background
    PubMed: PMID 18317253 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2007 (2 papers)

  1. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
    Grootendorst DC, Gauw SA, Verhoosel RM, et al. · Thorax · 2007 · Background
    PubMed: PMID 17573446 · NCT04090294 · Bronchiectasis
  2. Abdominal obesity and metabolic syndrome.
    Després JP, Lemieux I · Nature · 2007 · Background
    PubMed: PMID 17167477 · NCT01701934 (RAMBO) · Pulmonary Disease, Chronic Obstructive

2006 (1 paper)

  1. The metabolic syndrome in patients with chronic obstructive pulmonary disease.
    Marquis K, Maltais F, Duguay V, et al. · J Cardiopulm Rehabil · 2006 · Background
    PubMed: PMID 16056071 · NCT01701934 (RAMBO) · Pulmonary Disease, Chronic Obstructive

2005 (1 paper)

  1. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
    van Schalkwyk E, Strydom K, Williams Z, et al. · J Allergy Clin Immunol · 2005 · Background
    PubMed: PMID 16083782 · NCT04090294 · Bronchiectasis

2003 (1 paper)

  1. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.
    Sin DD, Man SF · Circulation · 2003 · Background
    PubMed: PMID 12654609 · NCT01701934 (RAMBO) · Pulmonary Disease, Chronic Obstructive

2002 (1 paper)

  1. Bronchiectasis.
    Barker AF · N Engl J Med · 2002 · Background
    PubMed: PMID 11986413 · NCT04090294 · Bronchiectasis

1999 (1 paper)

  1. cAMP enhances insulin secretion by an action on the ATP-sensitive K+ channel-independent pathway of glucose signaling in rat pancreatic islets.
    Yajima H, Komatsu M, Schermerhorn T, et al. · Diabetes · 1999 · Background
    PubMed: PMID 10331404 · NCT01862029 · Obesity

1997 (1 paper)

  1. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells.
    Faleiro L, Kobayashi R, Fearnhead H, et al. · EMBO J · 1997 · Background
    PubMed: PMID 9171342 · NCT05684484 · Colitis, Ulcerative

1990 (1 paper)

  1. Peripheral nerve surgery today: turning point or continuous development?
    Millesi H · J Hand Surg Br · 1990 · Background
    PubMed: PMID 2230491 · NCT01862029 · Obesity

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).